Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human ...

Inovio Pharmaceuticals ( (INO)) has provided an announcement. On December 29, 2025, INOVIO announced that the U.S. Food and Drug Administration accepted for review its Biologics License Application ...

INOVIO (INO) announced that the U.S. Food and Drug Administration, FDA, accepted the company’s Biologics License Application, BLA, for INO-3107 for review as a potential treatment for adults with RRP.

(RTTNews) - Inovio Pharmaceuticals, Inc. (INO) announced that its Biologics License Application for INO-3107, proposed for the treatment of adults with recurrent respiratory papillomatosis, has been ...

Inovio Pharmaceuticals Inc. (NASDAQ: INO) stock fell Monday after the U.S. Food and Drug Administration accepted the company’s Biologics License Application (BLA) for INO-3107 but raised concerns tied ...

PLYMOUTH MEETING, Pa., Dec. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from ...

Equity Insider News Commentary ? Global markets are undergoing a structural realignment as technology M&A volume surged to an ...

Inovio, a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, announced that the ...

Inovio shares were 22% lower, at $1.80, after the company said the Food and Drug Administration accepted its Biologics License Application for INO-3107 for review as a potential treatment for adults ...

Regeneron is to collaborate with Inovio to investigate a three-way immunotherapy combination against glioblastoma multiforme (GBM), an aggressive and hard-to-treat brain tumour. Regeneron’s drug is ...